Drug recall · November 6, 2019
AVKARE Ranitidine Hydrochloride Capsules 300 mg 500 Capsules recall
Why: CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
AVKARE Ranitidine Hydrochloride Capsules 300 mg 500 Capsules Rx Only NDC 42291-736-50 UPC 342291736504 Manufactured for: AvKARE, Inc. Pulaski, TN 38478
- Lots / codes
Lot 17709 Exp.01/31/2020 Lot 18460 Exp.02/29/2020 Lot 19853 Exp.09/30/2020 Lot 22362 Exp.11/30/2020 Lot 22579 Exp.11/30/2020
- Quantity
- 1351 bottles
- Company
- AVKARE Inc., Pulaski, TN
- Distribution
- CO, MO
- Initiated
- October 17, 2019 · Voluntary: Firm initiated
- Classified
- October 28, 2019
- Reported
- November 6, 2019
- Ended
- October 21, 2020
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Ranitidine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.